Stockreport

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacte...

Insmed, Inc.  (INSM) 
Last insmed, inc. earnings: 4/30 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF Study met primary endpoint of culture conversion (pPositive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive [Read more]